FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Anticoagulation in obese patients: challenges and strategies
1856PDF: 273HTML: 199XML: 85 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1301PDF: 232HTML: 88Supplementary: 67 -
PO15 | Venous thromboembolism risk associated with midline catheters and peripherally inserted central catheters: a systematic review and meta-analysis D. Santagata1, F. Subri1, F. Dentali1,2, M.P. Donadini1, I. Giarretta2 | 1Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como; 2Department of Internal Medicine, Ospedale di Circolo and Fondazione Macchi, Varese, Italy
445PDF: 0 -
PO37 | CLINICAL SIGNIFICANCE OF SYMPTOMATIC AND INCIDENTAL VENOUS THROMBOEMBOLISM IN CANCER PATIENTS TREATED WITH APIXABAN P. Hussaini1, T.L. Larsen2, W. Ghanima1|3, A.E.A. Dahm1|2 | 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 2Department of Hematology, Akershus University Hospital; Lørenskog, Norway; 3Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway
108PDF: 30 -
CS03 | Khorana risk score and genomic profiling for prediction of venous thromboembolism in ovarian cancer P. Santini, F. Mancinetti, S.M.P. D’Ambrosio, M. Bigossi, A. D’Errico, E. Fondi, G. Fracassa, E. Ianuà, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Polyclinic Foundation IRCCS, Roma, Italy
592PDF: 0 -
CO01 | Statin therapy for the prevention of venous thromboembolism in cancer patients: a systematic review and meta-analysis F. Catalani, R. Del Giorno, R. Canevascini, W. Ageno, L. Gabutti, G. Prouse, L. Giovannacci | Ospedale Regionale di Bellinzona, Switzerland.
551PDF: 0 -
PO10 | RISK OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETERS: RESULTS FROM THE VIENNA CAT-BLED STUDY B. Sunder-Plassmann 1, N, Vladic1, C. Englisch1, F. Moik1|3, V. Sunder-Plassmann2, A. Berghoff2, M. Preusser2, I. Pabinger1, C. Ay1 | 1Division of Hematology and Haemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 2Division of Oncology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 3Division of Oncology, Department of Internal Medicine, Medical University of Graz; Graz, Austria
112PDF: 35 -
PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM O. Iqbal | Loyola University Stritch School of Medicine, Maywood, IL, USA
109PDF: 25 -
PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS R. Cannas | Hemostasis and thrombosis Center, Ospedale Santissima Trinità, ASL Cagliari, Italy
125PDF: 24 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
619PDF: 0 -
PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE P. Holly1, J. Hudecek1, J. Chudej1, L. Valekova1, I. Plamenova1, E. Flochova1, R. Simonova1, J. Sokol1, J. Stasko1, M. Pietrzykova1|2, E. Vescecikova2 | 1Department of Hematology and Transfusion Medicine, University Hospital in Martin, Martin, Slovakia; 2National Transfusion Service, Martin, Slovakia
108PDF: 21 -
PO35 | Cerebral veins thrombosis in patients with and without myeloproliferative neoplasm: a real life retrospective monocentric study I. Bertozzi, M.T. Sartori, M. Zerbinati, G. Libralon, A. Galbiati, P. Simioni | First Medical Clinic, Department of Medicine - DIMED, Università degli Studi di Padova, Italy
473PDF: 0 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
455PDF: 0 -
CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis G. Gagliardi, E. Campello, A. Napolitano, B. Stocco, C. Di Gesù, G. Gobbo, I. Condonato, M. Allegra, G. Camporese, P. Scarinzi, R. Pesavento, F. Bilora, C. Bulato, A. Benetti, C. Samà, C. Portinari, G. Antonello, C. Goffi, L. Di Daniel, A. Zambon, L. Fabris, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
652PDF: 0 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
498PDF: 0 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
108PDF: 29 -
PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm1, N.H. Eide1, K. Hveem2|3|4, N. Van Es5|6, V.M. Morelli1|7, S.K. Braekkan1|7, J.B. Hansen1|7 | 1Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; 2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 3HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Research, St. Olav University Hospital, Trondheim, Norway; 5Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 6Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; 7Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
107PDF: 20 -
PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT S. Kozhukhov, N. Dovganych | SI “NSC “The M. D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 2Cardio-Oncology Center, Kyiv, Ukraine
100PDF: 28 -
CO10 | Multidimensional risk assessment of venous thromboembolism: an observational study comparing the Padua prediction score, Barthel index, and quality of life in hospitalized patients A. Mameli, S. Cornacchini, P. Schirru, F. Marongiu, D. Barcellona | Hemostasis and Thrombosis Unit, University of Cagliari, Italy
556PDF: 0 -
PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; 7Universidad Catolica San Antonio de Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology unit, Arles, France; 10Assistance Publique - Hôpitaux de Paris, AGEPS, France; 11Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département de Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France
109PDF: 21 -
PO68 | RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER AND MIGRAINE: A COHORT ANALYSIS AMONG DANISH NATIONAL HEALTH SURVEY PARTICIPANTS O. Rosenkrantz1, P. Szentkúti1, L. Amdisen1, E. Horváth-Puhó1, A.L. Pedersen1, H.E. Bøtker2, H. Elser1|3, J.P. Vandenbroucke1|4|5, H.T. Sørensen1 | 1Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Denmark; 2Department of Cardiology, Aarhus University Hospital, Department of Clinical Medicine, University of Aarhus, Denmark; 3Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 4Department of Clinical Epidemiology, Leiden University Medical School Leiden, The Netherlands; 5School of Hygiene and Tropical Medicine, London, UK
105PDF: 18 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
616PDF: 0 -
PO72 | Fondaparinux in patient with active tuberculosis T. Marrazzo1, R. Parrella2, A. Botta2, A. Pontarelli2, M.P. Ursi3, A. Karruli4, R. Albisinni5 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi, Napoli, Italy; 2UOC Malattie Infettive ad Indirizzo Respiratorio, Ospedale Cotugno Azienda dei Colli, Napoli, Italy; 3UOC MECAU Ospedale CTO Azienda dei Colli, Napoli, Italy; 4Malattie Infettive e Tropicali, Ospedale di Tirana, Albania; 5UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
487PDF: 0 -
PO13 | OUTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM AND SUBSEQUENT RISK OF CANCER S. Sørensen, D. Farkas, H. Sørensen | Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
81PDF: 27 -
PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy
597PDF: 0 -
PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; 4IRCCS NeuRomad, Pozzilli, Italy
498PDF: 0 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
94PDF: 22 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
510PDF: 0 -
CO52 | The impact of KRAS mutations on the risk of recurrent venous thromboembolism in patients with cancer-associated thrombosis and gastrointestinal neoplasms B. Cosmi1,2, S. Cavara2, M. Soldati2, L. Borgese2, M. Sartori2 | 1Angiology and Blood Coagulation Unit, Department of Medical and Surgical Sciences, University of Bologna; 2Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
470PDF: 0 -
PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE S. Gilani, H. Rubbani, A. Mackie | Cancer Centre, University Hospitals of North Midlands, Staffordshire, UK
103PDF: 26 -
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508CAT O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, P. Banerjee1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D.E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
97PDF: 24 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
520PDF: 0 -
PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY D. Siegal1|2, Z. O’Neill1|2, L. Nguyen3, N. Liu3, M. Carrier1|2, R. Sutradhar3|4 | 1Ottawa Hospital Research Institute, Ottawa; 2Department of Medicine, University of Ottawa, Ottawa; 3ICES, Toronto, Canada; 4Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
110PDF: 29 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
455PDF: 0 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
89PDF: 28 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
533PDF: 0 -
OC12 | RISK OF VENOUS THROMBOEMBOLISM AFTER REMOVAL OF AN UPPER EXTREMITY CENTRAL CATHETER ASSOCIATED WITH A DEEP VEIN THROMBOSIS IN CANCER PATIENTS M. Sartori, A. Trentini, S. Cavara, E. Favaretto, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
116PDF: 24 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
533PDF: 0 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
110PDF: 26 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
129PDF: 35 -
CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects S. Bolognini1,2, C. Ticozzi1, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
527PDF: 0 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
112PDF: 26 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
502PDF: 0 -
PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
192PDF: 36 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
459PDF: 0 -
PO61 | ACTN1-related thrombocytopenia and severe hyperhomocysteinemia: a case report A. Pozzi, G. Rosati, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, San Luigi Hospital, Orbassano (TO), Italy
444PDF: 0 -
PO33 | Whole blood hypercoagulable profiles in patients with rheumatoid arthritis L. Spiezia1, A. Giollo2, C. Samà1, A. Benetti1, L. Di Luozzo2, M. Salvato2, A. Doria2, P. Simioni1 | 1First Chair of Internal Medicine, Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova; 2Rheumatology Unit, Department of Medicine, University Hospital of Padova, Italy
493PDF: 0 -
PO45 | KHORANA RISK SCORE AND GENOMIC PROFILING FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN OVARIAN CANCER P. Santini, L. Mastrantoni, G. Anderson, F. Camarda, I. Marino, J. Preziosi, M. Buttarelli, M. Manfredelli, A. Minucci, F. Persiani, L. Giacò, T. Pasciuto, I. Conti, I. Mozzetta, F. Mancinetti, S. M. P. D’Ambrosio, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
100PDF: 32 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
446PDF: 0 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
93PDF: 29 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
602PDF: 0 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
107PDF: 26 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
100PDF: 35 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
505PDF: 0 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
91PDF: 32 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
94PDF: 29 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
80PDF: 29 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
106PDF: 25 -
CO17 | Clinical relevance of isolated anti-phosphatidylserine/ prothrombin antibody positivity A. Hoxha1, P. Žigon2,3, L. Katja2,3, S. Čučnik2,4, Ž. Rotar2,5, S. Gavasso1, P. Zerbinati1, G. Gobbo1, P. Simioni1 | 1University of Padua, Internal Medicine Unit, Thrombotic and Hemorrhagic Centre, Department of Medicine-DIMED, Padua, Italy; 2University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 3University of Primorska, Faculty of Mathematics, Natural Sciences and Information Technologies, Koper, Slovenia; 4University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia; 5University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
511PDF: 0
